Skip to main content

Published locations for Long-term efficacy and safety of risankizumab in PsA patients with inadequate response to csDMARD

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Long-term efficacy and safety of risankizumab in PsA patients with inadequate response to csDMARD

User login

  • Reset your password
  • /content/long-term-efficacy-and-safety-risankizumab-psa-patients-inadequate-response-csdmard
  • /rheumatology/article/259689/psoriatic-arthritis/long-term-efficacy-and-safety-risankizumab-psa
  • /breast-cancer-icymi/article/259689/psoriatic-arthritis/long-term-efficacy-and-safety-risankizumab
  • /b-cell-lymphoma-icymi/article/259689/psoriatic-arthritis/long-term-efficacy-and-safety-risankizumab
  • /psoriatic-arthritis-icymi/article/259689/psoriatic-arthritis/long-term-efficacy-and-safety